• AAPL 166.43
  • TSLA 145.55
  • AMZN 178.61
  • MSFT 406.73
  • INTC 34.38
  • EURUSD 1.0708
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. LSE /
  3. GSK.LSE

GlaxoSmithKline PLC (GSK LSE) stock market data APIs

p1650.5 -0.5(-0%) as of April 23, 2024

GlaxoSmithKline PLC Financial Data Overview

1651
1650.5
-
1656
1636.9961
1264.0404-1719.8
66 991 M
13.6625
4 086 M
30 328 M
28.9
0.039
0.268
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'GSK',
Type: 'Common Stock',
Name: 'GlaxoSmithKline PLC',
Exchange: 'LSE',
CurrencyCode: 'GBX',
CurrencyName: 'Pence sterling',
CurrencySymbol: 'p',
CountryName: 'UK',
CountryISO: 'GB',
ISIN: 'GB00BN7SWP63',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International/Domestic',
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
}

GlaxoSmithKline PLC Fundamental Data is available in our Financial Data APIs

  • Net Revenue 30 328 M
  • EBITDA 10 304 M
  • Earnings Per Share 1.2
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get GlaxoSmithKline PLC Earnings via APIs

  • Latest Release 2024-01-31
  • EPS/Forecast 28.63

Get GlaxoSmithKline PLC End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get GlaxoSmithKline PLC latest news via APIs

10 Best Weight Loss Drug Stocks to Buy Now

In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it's one of the biggest tren...

UPDATE 1-U.S. FDA approves Akebia's anemia drug

(Adds details from paragraph 2 onwards) March 27 (Reuters) - The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CK...
Do you have any questions?
support@eodhistoricaldata.com